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Standfirst  33 
The proliferation of surrogate endpoints for regulatory approval of new drugs poses major 34 
challenges for patients, clinicians, health technology assessment bodies and the wider evidence 35 
ecosystem. Dalia Dawoud and colleagues argue for raising the evidence standards for using 36 
surrogate endpoints by regulatory agencies and health technology assessment bodies. 37 
   38 
On 7 June 2021, the US Food and Drug Administration (FDA) granted accelerated approval to 39 
aducanumab for the treatment of Alzheimer’s Disease. The FDA based its decision on the drug’s 40 
amyloid-reducing effects despite evidence from several earlier studies that shrinkage of beta-amyloid 41 
protein plaques does not predictably delay cognitive impairment in patients.[1] The decision has 42 
drawn significant attention to the use of surrogate endpoints —laboratory values, radiographic 43 
images, or other physical measures that may serve as indicators of clinical outcomes such as 44 
symptom control or mortality— in clinical trials of new drugs.[2] In fact, the approval of 45 
aducanumab is only the latest example of growing regulatory reliance on surrogate endpoints.   46 
 47 
Using surrogate endpoints to measure whether a new drug works can reduce the duration, cost, and 48 
complexity of clinical trials prior to regulatory assessment, and facilitate faster patient access to new 49 
therapies, especially in chronic disease settings.[3] For example, in early-stage gastric cancer, clinical 50 
outcomes like overall survival—how long patients live after receiving treatment—are of primary 51 
interest to patients whilst surrogate endpoints such as disease-free survival potentially can be used to 52 
measure drug effects earlier.[4] In a recent evaluation, using surrogate endpoints in cancer drug trials 53 
reduced clinical development time by approximately 11 months compared with measuring overall 54 
survival. [3] However, the use of such endpoints can also have negative implications.  55 
 56 
Regulatory reliance on surrogate endpoints makes it challenging for HTA bodies, such as the 57 
National Institute for Health and Care Excellence (NICE), to make their decisions. The assessments 58 
conducted by HTA bodies typically include comparative clinical and cost-effectiveness 59 
considerations. When new drugs receive regulatory approval based on surrogate endpoints alone, 60 
assessing how well they work in terms of impact on patient-relevant clinical outcomes, such as 61 
health-related quality of life and survival, in the short and long term are fraught with considerable 62 
uncertainty.  63 
 64 
For patients and clinicians, surrogate endpoints can complicate treatment decisions.[5] Surrogate 65 
endpoints are not inherently meaningful on their own, and clinicians and patients may misinterpret 66 
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drug effects on surrogate endpoints as clinically meaningful improvements.[6] This matters, because 67 
drugs approved on the basis of surrogate endpoints may not ultimately influence patient-relevant 68 
clinical outcomes. In cancer, for example, most approved drugs with effects on surrogate endpoints 69 
such as response rates and progression-free survival (that were imagined to be predictive of patient-70 
relevant benefit) do not, in fact, improve quality of life or prolong survival.[7–9]  71 
 72 
There is a long history of drugs that were originally approved on the basis of surrogate endpoints and 73 
for which later studies failed to show evidence of clinical benefit.[10] An oft-cited example is 74 
bevacizumab for metastatic breast cancer.[11] In 2008, FDA granted accelerated approval to 75 
bevacizumab for the treatment of metastatic breast cancer based on its early effects on a surrogate 76 
endpoint, progression-free survival. In 2011, FDA revoked its approval for bevacizumab’s metastatic 77 
breast cancer indication when clinical trials failed to show that patients receiving bevacizumab lived 78 
longer than those receiving control treatment.  79 
 80 
Other examples include olaratumab, which extended progression-free survival but did not prolong 81 
survival for patients with soft-tissue sarcoma,[12] hydroxyprogesterone caproate, which effectively 82 
reduced the risk of recurrent births but did not improve neonatal outcomes,[13] and atezolizumab, 83 
which achieved a higher response rate compared to control but did not extend overall survival in 84 
patients with urothelial carcinoma .[14] In some cases, drugs initially approved on the basis of 85 
surrogate endpoints were later found to be harmful. For example, patients with multiple myeloma 86 
who received venetoclax had shorter survival than those who received a control treatment, despite 87 
evidence suggesting that venetoclax was more effective than control on the basis of progression-free 88 
survival).[15]  89 
 90 
In this article, we argue for more selective use of surrogate endpoints when evaluating new drugs. 91 
Surrogate endpoints should only be used in chronic disease settings, especially when collecting data 92 
on patient-relevant clinical outcomes requires trials with unattainably long follow up durations. 93 
When generating direct evidence on patient-relevant clinical outcomes is not possible, decision-94 
makers should systematically evaluate the relationship between surrogate endpoints and clinical 95 
outcomes.  96 
 97 
Regulatory enthusiasm for surrogate endpoints 98 
Over the past 3 decades, the proportion of clinical studies measuring the efficacy of new drugs via 99 
surrogate endpoints alone has increased, rising from fewer than one half in the mid-90s to 100 
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approximately 60% in 2015-2017.[16] In some therapeutic areas such as cancer, surrogate endpoints 101 
account for almost 80% of all clinical studies supporting regulatory approvals.[17] This means that in 102 
some therapeutic areas, only a minority of new drugs are now approved on the basis of evidence that 103 
they improve how patients feel or function, or how long they live. 104 
 105 
The recent proliferation of surrogate endpoints is partly due to the increase in the use of ‘expedited’ 106 
regulatory programs that are aimed at speeding up the development, review, and approval of 107 
drugs.[18] Over the past quarter century, lobbying by pharmaceutical companies has put pressure on 108 
policymakers to establish several expedited programs in Europe and the United States.[19] These 109 
programs also meet perceived patient demand for faster access to potentially effective therapies in 110 
therapeutic areas with significant unmet needs. In the US, the FDA “accelerated approval” pathway 111 
was established at the height of the HIV/AIDS crisis in the early 1990s. Other examples of expedited 112 
programs in the US include the “breakthrough therapy,” “priority review,” and “fast track” 113 
designations. Programs in Europe include the European Medicines Agency’s (EMA) “accelerated 114 
assessment” and “Priority Medicines” schemes.[20]  115 
 116 
The use of surrogate endpoints in certain expedited regulatory programs like the FDA’s accelerated 117 
approval pathway is linked to “conditional” approvals where drug manufacturers are legally 118 
mandated to conduct additional trials to demonstrate the clinical benefit of their products. Even when 119 
post-approval studies are required, however, clinical efficacy of drugs initially approved on the basis 120 
of surrogate endpoints is often subsequently “confirmed” on the basis of other surrogate 121 
endpoints.[21,22] For example, both pre-approval and mandated post-approval studies supporting 122 
FDA’s accelerated approval of lapatinib (for the treatment of postmenopausal women with HER2-123 
positive metastatic breast cancer) tested surrogate endpoints.[21] This practice may meet regulators’ 124 
expectations but falls far short of reliable evidence of patient benefit.  125 
 126 
Limited guidance from regulators and HTA bodies 127 
There is little consensus for defining a “valid” surrogate, as it is difficult to set specific thresholds to 128 
grade the strength of association with the final clinical outcome. Yet, some organisations such as the 129 
German Institute for Quality and Efficiency in Health Care (IQWiG) have prescriptive criteria for 130 
accepting surrogate endpoints. IQWiG sets a threshold for the lower bound of the confidence interval 131 
on the correlation coefficient (R ≥ 0.85) to conclude a high correlation exists between the surrogate 132 
and final clinical outcome.[23] Most other agencies have no similar cut-offs for accepting surrogate 133 
endpoints.  134 
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 135 
There is actually a long history of methodological efforts for evaluating surrogate endpoints. In 2009, 136 
Taylor and Elston [24] recommended a three-step framework, based on (i) biological plausibility 137 
alone, (ii) evidence of an observational association between the surrogate and the clinical endpoint at 138 
the individual patient level and (iii) evidence from multiple randomised trials showing that drugs 139 
improving the treatment effect on the surrogate also improve treatment effect on the final clinical 140 
outcome. This framework was further extended to quantify the expected treatment effect on the final 141 
clinical outcome based on the surrogate.[25]  142 
 143 
However, this framework is rarely used by regulatory agencies. In 2018, FDA published a table 144 
listing all surrogate endpoints that it has used in its assessments without disclosing any information 145 
about their usefulness in predicting clinical benefit.[26] Academic researchers are increasingly filling 146 
this evidence gap and examining the strength of the association between surrogate endpoints that are 147 
commonly used by regulators and patient-relevant clinical outcomes. [27,28] In a recent study, 148 
researchers found only weak or missing correlations between surrogate endpoints and survival in 149 
breast cancer using the Taylor and Elston framework.[29] In another analysis, researchers found that 150 
none of the surrogate endpoints used in EMA expedited approvals were evaluated in independent 151 
studies.[30] 152 
 153 
Similarly, HTA bodies rarely use this framework to evaluate surrogate endpoints,[31] Indeed, HTA 154 
guidance on the use of surrogate endpoints has been highly variable [32]. In a recent survey of 155 
methodological guidance by 73 organisations, only 40% gave specific consideration to using 156 
surrogates.[33] Such variation across HTA bodies yields heterogenous conclusions about the 157 
relevance of the same putative surrogate endpoints across different settings.[34]  158 
 159 
Evaluating surrogate endpoints 160 
Methodologists stress that evidence at the individual patient level alone is insufficient to evaluate 161 
surrogate endpoints especially when such evidence is obtained from a single trial.[35] This is 162 
because the observed surrogate-to-clinical outcome relationship for one drug may not hold for 163 
another, as it depends on the treatment’s mechanism of action.[35] For example, progression-free 164 
survival was previously shown to be a good surrogate for overall survival in advanced colorectal 165 
cancer based on evidence from trials of traditional chemotherapy.[36] However, Ciani et al. recently 166 
observed a weaker relationship between these endpoints in this setting for modern therapies with 167 
different mechanisms of action.[37]  168 
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 169 
Meta-analysis, which combines data from a number of randomised trials, is more appropriate for 170 
evaluating the association between the treatment effects on the candidate surrogate endpoint and on 171 
the final patient-relevant clinical outcome.[38] There is growing methodological consensus for using 172 
bivariate meta-analysis methods to evaluate the surrogate-to-final outcome relationships. [39–44] 173 
These methods take into account not only the correlation between the treatment effects (quantifying 174 
the surrogate relationship), but also uncertainty around this relationship, which is crucial for 175 
decision-making.[44,45]  176 
 177 
Table 1 lists selected examples of candidate surrogate endpoints evaluated using meta-analysis 178 
methods with authors’ conclusions regarding the strength of the surrogate relationship. It is perhaps 179 
not surprising that bevacizumab’s initial effect on progression-free survival never translated to 180 
prolonged survival for patients with metastatic breast cancer following FDA’s accelerated approval, 181 
as an earlier meta-analysis concluded that progression-free survival was not a good surrogate for 182 
overall survival in this setting.[36]  183 
 184 
A potential problem when evaluating surrogate endpoints is the limited amount of available 185 
randomised trial data in some areas, e.g., for drugs targeting genetic biomarkers in small patient 186 
populations. In such cases, novel bivariate network meta-analysis methods , [46] or hierarchical 187 
models,[47] allow for using readily available data on similar drugs or drug classes. These advanced 188 
methods are highlighted  in reports prepared by the NICE Decision Support Unit.[44,45] 189 
 190 
Way forward 191 
Regulators should be more selective in their use of surrogate endpoints. Surrogate endpoints are not 192 
useful – and should not be used – when a drug’s effect on the final clinical outcome can be observed 193 
within a relatively short time frame, e.g., in acute conditions.[48] Hence, using surrogate endpoints 194 
should be reserved for chronic disease settings when they can provide early and accurate 195 
measurement of a drug’s effect, especially when long follow-up is required before the final patient-196 
relevant clinical outcome can be assessed.[49] Even in such cases, regulators have other tools at their 197 
disposal to ensure patients who have exhausted all available treatment options can receive 198 
investigational treatments before regulatory approval. Such “expanded access” programs can bridge 199 
the access gap while evidence on patient-relevant endpoints accrues before regulatory approval. 200 
 201 
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When using surrogate endpoints is justified in selected chronic disease settings, regulators should 202 
consider the strength of available evidence on how well surrogates predict clinical benefit. The recent 203 
US accelerated approval of aducanumab for the treatment of Alzheimer’s disease demonstrates why 204 
this is essential. FDA’s decision was controversial in part because amyloid level changes had little to 205 
no effect on cognitive change in an earlier meta-analysis of randomized controlled trials.[1] Thus, it 206 
is still debatable whether the reduction in amyloid levels is an acceptable surrogate for cognition on 207 
the basis of current best evidence.   208 
 209 
In the absence of regulatory guidance, there are promising signs that HTA bodies are increasingly 210 
raising the bar for using surrogate endpoints. For example, NICE has recently proposed changes to 211 
its HTA methods to strengthen the evidence requirements for the use of surrogate endpoints, while 212 
still allowing flexibility when desired evidence is not available.[50,51]  Involving HTA bodies in 213 
early regulatory interactions with manufacturers may help align evidence requirements on surrogate 214 
endpoints. The UK Innovative Licensing and Access Pathway managed by the Medicines and 215 
Healthcare Products Regulatory Agency, NICE and the Scottish Medicines Consortium is aimed at 216 
facilitating such alignment.[52] 217 
 218 
Ultimately, regulatory and HTA decisions regarding the use of surrogate endpoints need to weigh the 219 
strength of available evidence on the validity of surrogates alongside other considerations such as 220 
unmet therapeutic need. When making such trade-offs, quantifying how well a candidate surrogate 221 
predicts the final clinical outcome can provide valuable information.[44,46] If recommended meta-222 
analysis methods are used, the strength (or weakness) of the surrogate will be reflected in the 223 
uncertainty around the predicted treatment effect on the final outcome. A weaker surrogate will yield 224 
a larger interval and hence greater uncertainty.  225 
 226 
Raising the bar for using surrogate endpoints by regulators and HTA bodies may increase the cost 227 
and duration of drug development. However, this need not hamper pharmaceutical innovation. In the 228 
past, regulatory guidance encouraging manufacturers to evaluate the cardiovascular outcomes of anti-229 
diabetic medications incentivised the generation of patient-centred evidence without adversely 230 
affecting research and development.[53,54]   231 
 232 
Greater involvement of patients (and organisations representing patients) in regulatory and HTA 233 
processes is also essential to ensure that the conditions for accepting surrogate endpoints for 234 
decision-making are adequately met. When using such endpoints is justified, patients can help ensure 235 
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that uncertainty related to surrogates is explicitly presented and taken into account. Patient input can 236 
also help guide regulatory and HTA decisions regarding the appropriate use of surrogate endpoints.   237 
 238 
Key messages 239 
• Surrogate endpoints are widely used by regulators to expedite the approval of new drugs, but 240 
most surrogate endpoints are not shown to be reliable predictors of outcomes that matter most 241 
to patients.  242 
• Regulators should only accept surrogate endpoints when generating data on clinical outcomes 243 
is not attainable.  244 
• When directly measuring drug effects on patient-relevant clinical outcomes would require 245 
trials of very substantial duration, regulators and health technology assessment bodies should 246 
systematically evaluate the appropriateness of surrogate endpoints using up to date meta-247 
analysis methods.  248 
 249 
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Table 1: Examples of candidate surrogate endpoints evaluated using meta-analysis and authors’ conclusions regarding the strength of 471 
the surrogate relationship 472 
 473 
Disease area Candidate 
surrogate endpoint 
Final clinical outcome Strength of the surrogate relationship, as reported by study authors  
Gastric cancer [8]  Disease-free survival Overall survival “Disease-free survival is an acceptable surrogate for overall survival in trials of 
cytotoxic agents for gastric cancer in the adjuvant setting” 
Multiple sclerosis 
[55] 
Relapse rate Expanded Disability 
Status Scale (EDSS) 
worsening 
“support the use of commonly used surrogate markers of expanded disability status 
scale worsening as endpoints in multiple sclerosis clinical trials” 
Immunoglobulin A 
nephropathy [56]  
Change in 
proteinuria 
Doubling of serum 
creatinine level, end-
stage renal disease, or 
death 
“supporting the use of an early reduction in proteinuria as a surrogate endpoint for 





Major coronary events “an approximately linear relationship between the absolute reductions in low-density 
lipoprotein cholesterol achieved in these trials and the proportional reductions in the 
incidence of coronary and other major vascular events” 
Advanced 






Overall survival “PFS is an acceptable surrogate for OS in advanced colorectal cancer” 
Advanced 
colorectal cancer in 
modern trials [37] 
Progression-free 
survival 
Overall survival “none of the end points were found to achieve the level of evidence (i.e., mean R2trial 
> 0.60) that has been set to select high or excellent correlation levels by common 








Overall survival “no end point could be demonstrated as a good surrogate for overall survival in these 
trials” 
Rectal cancer [57] Pathologic complete 
response and 
disease-free survival 
Overall survival “pathologic complete response and disease-free survival are not surrogate endpoints 
for 5-year survival in rectal cancer” 
Urinary cancer 
[58] 
Overall response rate 
and progression-free 
survival 
Overall survival “overall response rate and progression-free survival are not reliable surrogate end 
points for median overall survival in trials of PD-(L)1 inhibitor therapy for urinary 
cancers” 
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Renal cell 
carcinoma [59] 
Disease-free survival Overall survival “there was no strong correlation noted between 5-year disease-free survival and 5-
year overall survival rates or between treatment effects on these endpoints.” 
Prostate cancer 
[60] 
Event-free survival Overall survival “event-free survival is a weak surrogate for overall survival and is not suitable for 
use as an intermediate clinical end point to substitute for overall survival” 
HIV infection [61] CD4 count AIDS or death “CD4 cell count is a weak surrogate endpoint” 
Alzheimer’s 
disease [1] 
Amyloid levels Cognitive decline “reducing amyloid levels with drug treatment has, at most, a small effect on 
cognition” 
 474 
 475 
 476 
